Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology

Pediatr Blood Cancer. 2015 Aug;62(8):1326-36. doi: 10.1002/pbc.25513. Epub 2015 Apr 1.

Abstract

Cancer immunotherapy using antigen-specific T cells has broad therapeutic potential. Chimeric antigen receptors and bispecific antibodies can redirect T cells to kill tumors without human leukocyte antigens (HLA) restriction. Key determinants of clinical potential include the choice of target antigen, antibody specificity, antibody affinity, tumor accessibility, T cell persistence, and tumor immune evasion. For pediatric cancers, additional constraints include their propensity for bulky metastatic disease and the concern for late toxicities from treatment. Nonetheless, the recent preclinical and clinical developments of these T cell based therapies are highly encouraging.

Keywords: T cells; bispecific antibodies; chimeric antigen receptors; immunotherapy; pediatric oncology.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Bispecific / immunology
  • Antibodies, Bispecific / therapeutic use*
  • Antigens, Neoplasm / immunology*
  • Child
  • HLA Antigens / immunology
  • Humans
  • Immunotherapy / methods*
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / immunology
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology
  • Recombinant Fusion Proteins / therapeutic use
  • T-Lymphocytes, Cytotoxic / immunology*
  • T-Lymphocytes, Cytotoxic / transplantation

Substances

  • Antibodies, Bispecific
  • Antigens, Neoplasm
  • HLA Antigens
  • Receptors, Antigen, T-Cell
  • Recombinant Fusion Proteins